Key facts
- Active ingredient
- Cangrelor
- Drug class
- P2y12 Platelet Inhibitor
- Form
- Injectable
- Strength
- Cangrelor 50MG/VIAL
- Type
- Prescription (Rx)
- Brand or generic
- Generic
- Manufacturer
- Gland
- FDA application
- ANDA213551
What is Cangrelor?
From the FDA label:Cangrelor for injection is a direct-acting P2Y 12 platelet receptor inhibitor that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation. The chemical structure is similar to adenosine triphosphate (ATP). The chemical name of Cangrelor for injection is tetrasodium salt of N6-[2-(methylthio)ethyl]-2-[(3,3,3,trifluoropropyl)-5’-adenylic acid, monanhydride with (dichloromethylene) bisphosphonic acid. The empirical formula of Cangrelor tetrasodium is C 17 H 21 N 5 Cl 2 F 3 Na 4 O 12 P 3 S 2 and the molecular weight is 864.3 g/mol. The chemical structure is represented below: Cangrelor for Injection is a sterile white to off-white lyophilized powder for IV infusion. In addition to the active ingredient, Cangrelor, each single dose vial contains mannitol (158 mg), sorbitol (52 mg), and sodium hydroxide to adjust the pH. cangrelor-spl-structure
How to use
Cangrelor for injection is intended for administration via a dedicated IV line, only after reconstitution and dilution. ( 2.3 ) • Administer 30 mcg/kg intravenous (IV) bolus prior to PCI followed immediately by a 4 mcg/kg/min IV infusion for at least 2 hours or duration of procedure, whichever is longer. ( 2.1 ) • To maintain platelet inhibition after discontinuation of Cangrelor for injection infusion, administer an oral P2Y 12 platelet inhibitor. ( 2.2 ) 2.1 Recommended Dosing The recommended dosage of Cangrelor for injection is a 30 mcg/kg IV bolus followed immediately by a 4 mcg/kg/min IV infusion. Initiate the bolus infusion prior to PCI. The maintenance infusion should ordinarily be continued for at least 2 hours or for the duration of PCI, whichever is longer. 2.2 Transitioning Patients to Oral P2Y 12 Therapy To maintain platelet inhibition after discontinuation of Cangrelor for injection infusion, administer an oral P2Y12 platelet inhibitor, as described below: Ticagrelor: 180 mg at any time during Cangrelor for injection infusion or immediately after discontinuation [see Clinical Pharmacology (12.2) ]. Prasugrel: 60 mg immediately after discontinuation of Cangrelor for injection [see Drug Interactions (7.1) and Clinical Pharmacology (12.2) ] . Clopidogrel: 600 mg immediately after discontinuation of Cangrelor for injection [see Drug Interactions (7.1) and Clinical…
Side effects
The following adverse reactions are also discussed elsewhere in the labeling: • Bleeding [see Warnings and Precautions (5.1) ] The most common adverse reaction is bleeding ( 5.1 , 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma Limited at 866-770-7144 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of cangrelor has been evaluated in 13,301 subjects in controlled trials, in whom, 5,529 were in the CHAMPION PHOENIX trial. Bleeding There was a greater incidence of bleeding with cangrelor than with clopidogrel. No baseline demographic factor altered the relative risk of bleeding with cangrelor (see Table 1 and Figure 1). Table 1: Major Bleeding Results in the CHAMPION PHOENIX Study (Non-CABG related Bleeding) a CHAMPION PHOENIX Cangrelor (N=5529) Clopidogrel (N=5527) Any GUSTO bleeding, n (%) 857 (15.5) 602 (10.9) Severe/life-threatening b 11 (0.2) 6 (0.1) Moderate c 21 (0.4) 14 (0.3) Mild d 825 (14.9) 582 (10.5) Any TIMI bleeding, n (%) 45 (0.8) 17 (0.3) Major e 12 (0.2) 6 (0.1) Minor f 33 (0.6) 11 (0.2) Abbreviations: GUSTO: Global Utilization of…
Warnings
Important safety information
Bleeding: Like other drugs that inhibit platelet P2Y 12 function, cangrelor can increase the risk of bleeding ( 5.1 ) 5.1 Bleeding Drugs that inhibit platelet P2Y 12 function, including cangrelor, increase the risk of bleeding. In CHAMPION PHOENIX bleeding events of all severities were more common with cangrelor than with clopidogrel [see Adverse Reactions (6.1) ]. Bleeding complications with cangrelor were consistent across a variety of clinically important subgroups (see Figure 1). Once cangrelor is discontinued, there is no antiplatelet effect after an hour [see Clinical Pharmacology (12.3) ].
Who should not take Cangrelor
Significant active bleeding ( 4.1 ) • Hypersensitivity to cangrelor or any component of the product ( 4.2 ) 4.1 Significant Active Bleeding Cangrelor is contraindicated in patients with significant active bleeding [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. 4.2 Hypersensitivity Cangrelor is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product [see Adverse Reactions (6.1) ].
Overdose — what happens if you take too much
There is no specific treatment to reverse the antiplatelet effect of Cangrelor for injection but the effect is gone within one hour after the drug is discontinued. In clinical trials, 36 patients received an overdose of Cangrelor for injection, ranging from 36 to 300 mcg/kg (bolus dose) or 4.8 to 13.7 mcg/kg/min (infusion dose). The maximum overdose received was 10 times the PCI bolus dose or 3.5 times the PCI infusion dose in 4 patients. No clinical sequela were noted as a result of overdose following completion of Cangrelor for injection therapy.
U.S. Poison Control: call or text 1-800-222-1222 (free, 24/7). In an emergency call 911. From the FDA label; not medical advice.
Interactions
Clopidogrel: Do not administer during cangrelor infusion. ( 7.1 ) • Prasugrel: Do not administer during cangrelor infusion. ( 7.1 ) 7.1 Thienopyridines Clopidogrel or prasugrel administered during cangrelor infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer Clopidogrel or prasugrel after cangrelor infusion is discontinued [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3) ].
Storing Cangrelor, and how long it keeps
Quoted from this product’s own FDA label. Storage belongs to the product and its device, not to the drug in general — a pen and a tablet of the same medicine are kept completely differently.
- “Diluted Cangrelor for injection is stable for up to 12 hours in 5% Dextrose Injection and 24 hours in Normal Saline at Room Temperature.”
Drug class
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- Is there a coupon or discount for Cangrelor?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Cangrelor. To pay less, Cangrelor is already a generic — usually the lowest-cost version — so the main levers are comparing cash prices between pharmacies and using a pharmacy discount-card service. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Cangrelor?
- Cangrelor is marketed by Gland. You can see Gland's full profile, rating, and other products on pharmaranks.
- Is Cangrelor a brand-name or generic drug?
- Cangrelor is a generic medication; its active ingredient is Cangrelor. Generics contain the same active ingredient as the brand-name original and are usually lower cost.
- Is Cangrelor available over the counter?
- No. Cangrelor is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Cangrelor come in?
- Cangrelor is currently marketed as injectable, per the FDA's National Drug Code Directory.
- What class of drug is Cangrelor?
- Cangrelor is classified as p2y12 platelet inhibitor, per the FDA's Established Pharmacologic Class.
- Is Cangrelor FDA-registered?
- Cangrelor is on record with the U.S. FDA under application number ANDA213551. You can verify this on its official FDA label.
- Is Cangrelor safe?
- There's no single safe-or-not verdict, and we don't yet have a composite recall-safety score for Cangrelor. Review its FDA-label side effects and warnings below, and always consult a licensed professional.
- What are the side effects of Cangrelor?
- Cangrelor's side effects are taken directly from its FDA label. From the label: The following adverse reactions are also discussed elsewhere in the labeling: • Bleeding [see Warnings and Precautions (5.1) ] The most common adverse reaction is bleeding ( 5.1 , 6.1 ) To report SUSPECTED ADVERSE REACTIONS,… Both common and serious reactions are documented in full on this page. This is general reference from the FDA, not medical advice — always consult a professional.
Clinical content sourced from the FDA label via openFDA (U.S. FDA). View the FDA label on DailyMed → Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Cangrelor head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
cangrelor
New